Analysis of the main mechanism of action and efficacy of Guanfacine

Guanfacine is a selectiveα2A-adrenergic receptor agonist. It was originally used to treat hypertension, but its unique central nervous mechanism of action also makes it show new value in neuropsychiatric diseases. Its core mechanism of action is to inhibit the release of norepinephrine by activating α2A receptors in the brainstem and prefrontal cortex, thereby reducing sympathetic nerve activity and placing the nervous system in a more stable state.

In attention deficit hyperactivity disorder (ADHD), guanfacine can improve the neural network function of the prefrontal cortex, enhance concentration, control impulsive behavior, and improve sleep quality. It is especially suitable for children or adolescents with ADHD accompanied by anxiety or insomnia symptoms. Compared with commonly used central stimulant drugs such as methylphenidate, guanfacine has non-stimulant characteristics and a lower risk of addiction. It is especially suitable for patients who cannot tolerate stimulants or are at risk of abuse.

In addition, guanfacine has also been explored for use in areas such as withdrawal syndrome, tic disorders, and impulse control issues related to the autism spectrum. Its extended-release preparation (Guanfacine ER, trade name Intuniv) has received particular clinical attention because its release rate is stable, easy to take before bed, and can improve mood swings and behavioral impulsivity during the day. It is worth noting that due to its antihypertensive effect, guanfacine has common side effects such as mild dizziness, drowsiness, and hypotension during the initial administration or dosage increase stage, but these can usually be alleviated by adjusting the dosage and administration time.

Overall, guanfacine provides a low-risk, high-tolerance drug option for ADHD and related mental and behavioral problems by improving the regulatory function of norepinephrine, and has gradually been included in more international guidelines as one of the standard non-stimulant medications.

Reference materials:https://go.drugbank.com/drugs/DB01018